Is Trifluridine Tipiracil Tablets (Lonsurf) on the market?

Trifluridine/Tipiracil tablets (Lonsurf) were approved by the U.S. Food and Drug Administration (FDA) in September 2015 and are marketed under the trade name Lonsurf. It is a combination product containing trifluridine/Tipiracil and is used to treat adult patients with metastatic colorectal cancer and metastatic gastric cancer who have previously received chemotherapy and other treatments.

Trifluridine tipiracil tablets were approved by the European Medicines Agency (EMA) in April 2016, believing that its benefits in prolonging the survival of patients with previously treated metastatic colorectal cancer and metastatic gastric cancer are important. Regarding its safety, although the side effects of trifluridine and tipiracil tablets can be serious, they are consistent with the expectations of this type of drug, that is, the benefits outweigh the risks.

The original drug of trifluridine tipiracil tablets was approved by the State Food and Drug Administration in August 2019 for domestic marketing. The trade name is Langsif, but it has not yet passed the relevant regulations to enter the scope of medical insurance. The price of each box may be around 6,000 yuan, and the price of each box of the Hong Kong version may be more than 10,000 yuan (the price may fluctuate due to the exchange rate).

The Japanese version of the original trifluridine tipiracil tablets marketed overseas may cost around more than 5,000 yuan per box (the price may fluctuate due to exchange rates). There are also cheaper generic versions of trifluridine and tipiracil tablets available overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of each box produced by an Indian pharmaceutical factory may be around more than 1,000 yuan (the price may fluctuate due to exchange rates).